The ongoing phase II RGX-202-002 trial is comparing second-line FOLFIRI-bevacizumab in combination with ompenaclid versus placebo in patients with KRAS-mutated advanced CRC (NCT05983367). Here, KRAS is linked to colorectal carcinoma.